Piclidenoson is used for the treatment of patients with moderate to severe psoriasis. Credit: Eszter Miller from Pixabay.

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted positive opinion for Can-Fite BioPharma’s registration plan submission for Phase III trial of Piclidenoson for the treatment of patients with moderate to severe psoriasis.

The agency has accepted the pivotal trial and the safety of the 3mg dose of Piclidenoson given two times a day.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Can-Fite plans to commence the prospective, double-blind, placebo-controlled and randomised trial of Piclidenoson to demonstrate its clinical efficacy and safety.

This will help the company submit a marketing authorization application.

Can-Fite CEO Dr Pnina Fishman said: “Piclidenoson’s oral dosage and excellent safety record combined with its progressive effectiveness over time make it ideally suited for the treatment of psoriasis, a chronic disease.

“Should this market registration study produce positive results similar to our COMFORT study, we believe Piclidenoson will be well positioned in a very large market which needs more safe and effective oral drug options.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The company’s COMFORT study of Piclidenoson was found to meet its primary endpoint with statistically significant improvement against placebo in patients with psoriasis.

The Phase III multicentre, randomised, placebo- and active-controlled, double-blind study evaluated the efficacy and safety of the therapy in over 400 adult patients with moderate to severe plaque psoriasis.

It also showed excellent safety profile in psoriasis patients.

The company has also submitted the chemistry, manufacturing, and controls (CMC), nonclinical data, and clinical pharmacology data to the agency.

In addition, it is submitting a comparable data package to the US Food and Drug Administration (FDA).